Ms. Stephanie Holland previously managed Clinical Programs in therapeutic areas covering Influenza, Oncology, Hepatitis B and Anthrax at Altimmune, Inc. She has held various positions in biotech and public health organizations managing the execution of global Phase I-IV clinical trials. At APT she leverages her knowledge of clinical research processes to strategically execute clinical programs while implementing solutions to meet the unique needs of PhageBank Therapy. This work ensures that studies are conducted in compliance with SOPs, ICH/GCP guidelines and industry best practices. Ms. Holland earned her Bachelor of Science in Public Health Education from North Carolina Central University and attended Johns Hopkins University.